Celltrion to Evaluate Remsima (biosimilar- infliximab) Against COVID-19 in the UK
Shots:
- Celltrion collaborates with the University of Oxford and University Hospitals Birmingham to study the efficacy of Remsima (CT-P13) as a potential treatment for COVID-19
- UHB will test a series of new drugs in a CATALYST trial. If the CATALYST study indicates benefit CT-P13 it would then be assessed in larger-scale studies in one of the UK national platform trials RECOVERY or REMAP-CAP
- Additionally- UHB will evaluate Izana Bioscience’s Namilumab (IZN-101) which is a mAb in a late-stage studies for RA and ankylosing spondylitis
Click here to read full press release/ article
Ref: UHB | Image: Celltrion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com